A clinicopathological study of multidrug therapy in borderline tuberculoid leprosy.
A study was undertaken to evaluate the efficacy of multidrug therapy as per WHO recommendation in 50 fresh cases (46 males and 4 females) suffering from borderline tuberculoid leprosy. All were given multidrug therapy consisting of rifampicin 600 mg once a month and dapsone 100 mg daily for 6 months. At the end of 6 months all were evaluated clinically and histopathological examinations of the lesions were studied. The lesions were still active in 60% of patients clinically; 32% cases receiving multidrug therapy had shown marked improvement. Histologically lymphocytic infiltration in skin still persisted in all the slides examined and nerve infiltration was still present in 68% of cases at the end of 6 months after receiving multidrug therapy. The study shows that treatment with multidrug regimen for 6 months may not be sufficient to treat borderline tuberculoid leprosy cases.
Kar
P K
PK
Department of Dermatology, STD and Leprosy, Command Hospital (SC), Pune.
Arora
P N
PN
Ramasastry
C V
CV
Dhaka
R S
RS
D000293:Adolescent; D000328:Adult; D003622:Dapsone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015439:Leprosy, Borderline / Q000188:drug therapy*; D015441:Leprosy, Tuberculoid / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012293:Rifampin / Q000627:therapeutic use*; D016896:Treatment Outcome
D003622:Dapsone; D012293:Rifampin